A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
A Study of Daratumumab
Phase 3 Recruiting
500 enrolled
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 2/3 Recruiting
660 enrolled
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1 Recruiting
140 enrolled
MajesTEC-7
Phase 3 Recruiting
1,590 enrolled
Iber-KDd
Phase 2 Recruiting
30 enrolled
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Phase 2 Recruiting
20 enrolled
MagnetisMM-6
Phase 3 Recruiting
1,116 enrolled
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 Recruiting
1,450 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 Recruiting
130 enrolled
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 Recruiting
246 enrolled
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1/2 Recruiting
440 enrolled
MAGNETISMM-5
Phase 3 Recruiting
944 enrolled
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Phase 3 Recruiting
1,000 enrolled
FASTER
Phase 2 Recruiting
100 enrolled
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Phase 1 Recruiting
317 enrolled
MASTER-2
Phase 2 Recruiting
300 enrolled
DREAMM-10
Phase 3 Recruiting
520 enrolled
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Phase 2 Recruiting
40 enrolled
HD10/DSMMXX
Phase 2 Recruiting
160 enrolled
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Phase 1 Recruiting
100 enrolled
STOMP
Phase 1/2 Recruiting
300 enrolled
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Phase 2 Recruiting
23 enrolled
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
Recruiting
450 enrolled
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 Recruiting
15 enrolled
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Phase 2 Recruiting
43 enrolled
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Phase 1/2 Recruiting
37 enrolled
IFM2021-01
Phase 2 Recruiting
74 enrolled
FUMANBA-03
Phase 3 Recruiting
240 enrolled
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4 Recruiting
59 enrolled
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Phase 3 Recruiting
510 enrolled
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Phase 1/2 Recruiting
128 enrolled
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Recruiting
15 enrolled
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Phase 2/3 Recruiting
176 enrolled
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Phase NA Recruiting
100 enrolled
HOVON174MM
Phase 3 Recruiting
599 enrolled
TALTEC
Phase 2 Recruiting
50 enrolled
TAURUS
Phase 2 Recruiting
200 enrolled
DARVIVA
Phase 3 Recruiting
252 enrolled